Prognostic Significance of Micro RNA 150 Marker in BCR-ABL Positive Chronic Myeloid Leukaemia Patients on Imatinib Mesylate

International Journal of Contemporary Pediatrics
doi 10.18203/2349-3291.ijcp20173763
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Medip Academy

Related search

Contribution of BCR-ABL Kinase Domain Mutations to Imatinib Mesylate Resistance in Philadelphia Chromosome Positive Malaysian Chronic Myeloid Leukemia Patients

Hematology Reports
Hematology
2012English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research
Cancer ResearchOncology
2004English

Clinical and Genetic Studies of ETV6/ABL1-positive Chronic Myeloid Leukaemia in Blast Crisis Treated With Imatinib Mesylate

British Journal of Haematology
Hematology
2003English

The Use of Imatinib Resistance Mutation Analysis to Direct Therapy in Philadelphia Chromosome/BCR-Abl1 Positive Chronic Myeloid Leukaemia Patients Failing Imatinib Treatment, in Patan Hospital, Nepal

British Journal of Haematology
Hematology
2017English

E19a2 BCR-ABL Fusion Transcript in Typical Chronic Myeloid Leukaemia: A Report of Two Cases

Journal of Clinical Pathology
MedicineForensic MedicinePathology
2006English

Transcription-Mediated Amplification and Hybridisation Protection Assay to Determine BCR-ABL Transcript Levels in Patients With Chronic Myeloid Leukaemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2002English

IPO-trimethylation of Histone H3-Lysine9associated With P210 BCR-ABL Tyrosine Kinase of Chronic Myeloid Leukaemia

British Journal of Haematology
Hematology
2008English

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

Blood
BiochemistryImmunologyCell BiologyHematology
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy